107 related articles for article (PubMed ID: 22727372)
1. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).
Gomaa MS; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Oct; 54(19):6803-11. PubMed ID: 21838328
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.
Gomaa MS; Bridgens CE; Aboraia AS; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
J Med Chem; 2011 Apr; 54(8):2778-91. PubMed ID: 21428449
[TBL] [Abstract][Full Text] [Related]
5. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.
Gomaa MS; Armstrong JL; Bobillon B; Veal GJ; Brancale A; Redfern CP; Simons C
Bioorg Med Chem; 2008 Sep; 16(17):8301-13. PubMed ID: 18722776
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]-1H-triazoles.
Pautus S; Yee SW; Jayne M; Coogan MP; Simons C
Bioorg Med Chem; 2006 Jun; 14(11):3643-53. PubMed ID: 16458519
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.
Pautus S; Aboraia AS; Bassett CE; Brancale A; Coogan MP; Simons C
J Enzyme Inhib Med Chem; 2009 Apr; 24(2):487-98. PubMed ID: 18608743
[TBL] [Abstract][Full Text] [Related]
8. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.
Sun B; Liu K; Han J; Zhao LY; Su X; Lin B; Zhao DM; Cheng MS
Bioorg Med Chem; 2015 Oct; 23(20):6763-73. PubMed ID: 26365710
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
Mulvihill MJ; Kan JL; Beck P; Bittner M; Cesario C; Cooke A; Keane DM; Nigro AI; Nillson C; Smith V; Srebernak M; Sun FL; Vrkljan M; Winski SL; Castelhano AL; Emerson D; Gibson N
Bioorg Med Chem Lett; 2005 Mar; 15(6):1669-73. PubMed ID: 15745819
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
Nelson CH; Buttrick BR; Isoherranen N
Curr Top Med Chem; 2013; 13(12):1402-28. PubMed ID: 23688132
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.
Njar VC
Mini Rev Med Chem; 2002 Jun; 2(3):261-9. PubMed ID: 12370067
[TBL] [Abstract][Full Text] [Related]
13. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
[TBL] [Abstract][Full Text] [Related]
14. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells.
Sonneveld E; van den Brink CE; van der Leede BM; Schulkes RK; Petkovich M; van der Burg B; van der Saag PT
Cell Growth Differ; 1998 Aug; 9(8):629-37. PubMed ID: 9716180
[TBL] [Abstract][Full Text] [Related]
15. Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.
Diaz P; Huang W; Keyari CM; Buttrick B; Price L; Guilloteau N; Tripathy S; Sperandio VG; Fronczek FR; Astruc-Diaz F; Isoherranen N
J Med Chem; 2016 Mar; 59(6):2579-95. PubMed ID: 26918322
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).
Zhao D; Sun B; Ren J; Li F; Song S; Lv X; Hao C; Cheng M
Bioorg Med Chem; 2015 Mar; 23(6):1356-65. PubMed ID: 25684424
[TBL] [Abstract][Full Text] [Related]
17. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Patel JB; Huynh CK; Handratta VD; Gediya LK; Brodie AM; Goloubeva OG; Clement OO; Nanne IP; Soprano DR; Njar VC
J Med Chem; 2004 Dec; 47(27):6716-29. PubMed ID: 15615521
[TBL] [Abstract][Full Text] [Related]
18. Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.
Sun B; Song S; Hao CZ; Huang WX; Liu CC; Xie HL; Lin B; Cheng MS; Zhao DM
J Mol Graph Model; 2015 Mar; 56():10-9. PubMed ID: 25541526
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2, 3 or 5-(alpha-azolylbenzyl)-1H-indoles.
Le Borgne M; Marchand P; Le Baut G; Ahmadi M; Smith HJ; Nicholls PJ
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):155-8. PubMed ID: 12943199
[TBL] [Abstract][Full Text] [Related]
20. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
